5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl methanesulfonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl methanesulfonate
• 英文别名: 5-(5-Chlorothiophen-2-yl)isoxazol-3-ylmethyl methanesulfonate；[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl methanesulfonate
• 化学式: C₉H₈ClNO₄S₂
• 分子量: 293.752
• InChiKey: WKFXNWVTIMYEBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  106
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-哌嗪酮 、 5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl methanesulfonate 以89%的产率得到4-((5-(5-chlorothiophen-2-yl)isoxazol-3-yl)methyl)piperazin-2-one
  参考文献：
  名称：

  Dimerization of β-tryptase inhibitors, does it work for both basic and neutral P1 groups?

  摘要：

  The tetrameric folding of beta-tryptase and the pair-wise distribution of its substrate binding sites offer a unique opportunity for development of inhibitors that span two adjacent binding sites. A series of dimeric inhibitors with two basic P1 moieties was discovered using this design strategy and exhibited tight-binder characteristics. Using the same strategy, an attempt was made to design and synthesize dimeric inhibitors with two neutral-P1 groups in hope to exploit the dimeric binding mode to achieve a starting point for further optimization. The unsuccessful attempt, however, demonstrated the important role played by Ala190 in neutral-P1 binding and casted further doubt on the possibility of developing neutral-P1 inhibitors for beta-tryptase. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.021
• 作为产物：
  描述：

  2-乙酰基-5-氯噻酚 在 sodium tetrahydroborate 、 盐酸羟胺 作用下， 生成 5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl methanesulfonate
  参考文献：
  名称：

  Dimerization of β-tryptase inhibitors, does it work for both basic and neutral P1 groups?

  摘要：

  The tetrameric folding of beta-tryptase and the pair-wise distribution of its substrate binding sites offer a unique opportunity for development of inhibitors that span two adjacent binding sites. A series of dimeric inhibitors with two basic P1 moieties was discovered using this design strategy and exhibited tight-binder characteristics. Using the same strategy, an attempt was made to design and synthesize dimeric inhibitors with two neutral-P1 groups in hope to exploit the dimeric binding mode to achieve a starting point for further optimization. The unsuccessful attempt, however, demonstrated the important role played by Ala190 in neutral-P1 binding and casted further doubt on the possibility of developing neutral-P1 inhibitors for beta-tryptase. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.021

文献信息

• IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA
  申请人：KALLUS Christopher

  公开号：US20080262028A1

  公开（公告）日：2008-10-23

  The present invention is directed to a compound of formula I: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.

  本发明涉及一种式I化合物： 或式I化合物的任何立体异构体形式，或这些形式的任何比例的混合物，或式I化合物的生理可接受盐，该化合物抑制酶TAFIa（活化的凝血酶可激活的纤维蛋白溶解抑制剂），以及涉及它们的制备方法及其用于治疗说明书中所述疾病的使用，其中取代基如说明书中所述。
• Benzimidazole-derivatives as factor Xa inhibitors
  申请人：Nazare Marc

  公开号：US20050009829A1

  公开（公告）日：2005-01-13

  The present invention relates to compounds of the formula I, wherein R 0 , R 1 , R 2 , Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0、R1、R2、Q、V、G和M如本文所定义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，适用于心血管疾病如血栓栓塞病或再狭窄的治疗和预防。它们是血凝酶酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可以应用于存在因子Xa和/或因子VIIa的不良活性或者需要抑制因子Xa和/或因子VIIa以治疗或预防的情况。此外，本发明还涉及制备式I的化合物的方法，它们的使用，尤其是作为药物的活性成分，以及包含它们的制药制剂。
• Imidazole derivatives as inhibitors of TAFIa
  申请人：Sanofi-Aventis

  公开号：US08044208B2

  公开（公告）日：2011-10-25

  The present invention is directed to a compound of formula I: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.

  本发明涉及公式I的化合物，或公式I的任何立体异构体形式，或这些形式的任意比例混合物，或公式I的生理上可接受的盐，这些化合物抑制酶TAFIa（活化凝血酶活化的纤溶抑制剂），以及它们的制备方法和用于治疗所述疾病的用途，其中取代基如说明书所述。
• BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1636216A1

  公开（公告）日：2006-03-22
• IMIDAZOLDERIVATE ALS INHIBITOREN VON TAFI-A
  申请人：Sanofi-Aventis

  公开号：EP1937673A1

  公开（公告）日：2008-07-02